{"id":"kras","name":"KRAS","symbol":"KRAS","route":"/targets/kras/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133703","uniprot":"https://www.uniprot.org/uniprotkb/P01116/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P01116","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2189121","open-targets":"https://platform.opentargets.org/target/ENSG00000133703","civic":"https://civicdb.org/genes/3845/summary","oncokb":"https://www.oncokb.org/gene/KRAS","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRAS","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=KRAS","depmap":"https://depmap.org/portal/gene/KRAS?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000133703-KRAS","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3845","omim":"https://www.omim.org/entry/190070"}],"products":[{"id":"adagrasib","name":"Adagrasib","status":"approved","modality":"Small-molecule inhibitor (KRAS G12C)","route":"/drugs/adagrasib/"},{"id":"avutometinib-defactinib","name":"Avutometinib + defactinib","status":"approved","modality":"Small-molecule RAF/MEK clamp + FAK inhibitor","route":"/drugs/avutometinib-defactinib/"},{"id":"calderasib","name":"Calderasib","status":"phase-3","modality":"small molecule","route":"/drugs/calderasib/"},{"id":"daraxonrasib","name":"Daraxonrasib","status":"approved","modality":"Small-molecule pan-RAS(ON) inhibitor","route":"/drugs/daraxonrasib/"},{"id":"divarasib","name":"Divarasib","status":"phase-3","modality":"Small-molecule inhibitor (KRAS G12C)","route":"/drugs/divarasib/"},{"id":"eli-002-7p","name":"ELI-002 7P","status":"phase-2","modality":"Off-the-shelf lymph-node-targeted KRAS peptide vaccine","route":"/drugs/eli-002-7p/"},{"id":"elironrasib","name":"Elironrasib","status":"phase-2","modality":"Small-molecule RAS(ON) G12C-selective inhibitor","route":"/drugs/elironrasib/"},{"id":"fulzerasib","name":"Fulzerasib","status":"approved","modality":"Small-molecule covalent KRAS G12C inhibitor","route":"/drugs/fulzerasib/"},{"id":"garsorasib","name":"Garsorasib","status":"approved","modality":"Small-molecule covalent KRAS G12C inhibitor","route":"/drugs/garsorasib/"},{"id":"gfh375","name":"GFH375","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/gfh375/"},{"id":"glecirasib","name":"Glecirasib","status":"approved","modality":"Oral covalent KRAS G12C inhibitor","route":"/drugs/glecirasib/"},{"id":"guardant360-cdx","name":"Guardant360 CDx","status":"approved","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","route":"/drugs/guardant360-cdx/"},{"id":"incb161734","name":"INCB161734","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/incb161734/"},{"id":"jdq443","name":"JDQ443","status":"phase-3","modality":"small molecule","route":"/drugs/jdq443/"},{"id":"jyp0015","name":"JYP0015","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/jyp0015/"},{"id":"mrtx1133","name":"MRTX1133","status":"phase-1","modality":"Small-molecule non-covalent KRAS G12D inhibitor","route":"/drugs/mrtx1133/"},{"id":"olomorasib","name":"Olomorasib","status":"phase-3","modality":"Small-molecule inhibitor (KRAS G12C)","route":"/drugs/olomorasib/"},{"id":"resolution-ctdx-first","name":"Resolution ctDx FIRST","status":"approved","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","route":"/drugs/resolution-ctdx-first/"},{"id":"setidegrasib","name":"Setidegrasib","status":"phase-3","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","route":"/drugs/setidegrasib/"},{"id":"sotorasib","name":"Sotorasib","status":"approved","modality":"Small-molecule inhibitor (KRAS G12C)","route":"/drugs/sotorasib/"},{"id":"tempus-xt-cdx","name":"Tempus xT CDx","status":"approved","modality":"Tissue NGS companion diagnostic test (648 genes, tumour-normal)","route":"/drugs/tempus-xt-cdx/"},{"id":"therascreen-cdx","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","status":"approved","modality":"Real-time PCR companion diagnostic test family","route":"/drugs/therascreen-cdx/"},{"id":"vs-7375","name":"VS-7375","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/vs-7375/"},{"id":"zoldonrasib","name":"Zoldonrasib","status":"phase-2","modality":"Small-molecule RAS(ON) G12D-selective inhibitor","route":"/drugs/zoldonrasib/"}],"trials":[{"id":"krascendo-1","name":"Krascendo 1","nct":"NCT06497556","phase":"3","status":"positive"},{"id":"rasolute-302","name":"RASolute 302","nct":"NCT06625320","phase":"3","status":"positive"},{"id":"krystal-12","name":"KRYSTAL-12","nct":"NCT04685135","phase":"3","status":"positive"},{"id":"cairo5","name":"CAIRO5","nct":"NCT02162563","phase":"3","status":"mixed"},{"id":"codebreak-300","name":"CodeBreaK 300","nct":"NCT05198934","phase":"3","status":"positive"},{"id":"notable-trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","nct":"NCT02395016","phase":"3","status":"positive"},{"id":"codebreak-200","name":"CodeBreaK 200","nct":"NCT04303780","phase":"3","status":"positive"},{"id":"new-epoc","name":"New EPOC","nct":"ISRCTN22944367","phase":"3","status":"negative"},{"id":"calgb-80405","name":"CALGB/SWOG 80405","nct":"NCT00265850","phase":"3","status":"mixed"},{"id":"petacc-8","name":"PETACC-8","nct":"NCT00265811","phase":"3","status":"negative"},{"id":"prime","name":"PRIME","nct":"NCT00364013","phase":"3","status":"positive"},{"id":"n0147","name":"Alliance N0147","nct":"NCT00079274","phase":"3","status":"negative"},{"id":"coin","name":"MRC COIN","nct":"ISRCTN27286448","phase":"3","status":"negative"},{"id":"crystal-fire3","name":"CRYSTAL & FIRE-3","nct":"NCT00154102","phase":"3","status":"positive"},{"id":"co-17","name":"NCIC CO.17","nct":"NCT00079066","phase":"3","status":"positive"},{"id":"nct07190248","name":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","nct":"NCT07190248","phase":"3","status":"recruiting"},{"id":"nct06997497","name":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","nct":"NCT06997497","phase":"3","status":"recruiting"},{"id":"nct07554339","name":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","nct":"NCT07554339","phase":"3","status":"recruiting"},{"id":"nct05920356","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","nct":"NCT05920356","phase":"3","status":"recruiting"},{"id":"nct06793215","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","nct":"NCT06793215","phase":"3","status":"recruiting"},{"id":"nct06875310","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","nct":"NCT06875310","phase":"3","status":"recruiting"},{"id":"nct06345729","name":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","nct":"NCT06345729","phase":"3","status":"recruiting"},{"id":"nct06119581","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","nct":"NCT06119581","phase":"3","status":"recruiting"},{"id":"nct07566052","name":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","nct":"NCT07566052","phase":"3","status":"recruiting"},{"id":"nct07522073","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","nct":"NCT07522073","phase":"3","status":"recruiting"},{"id":"nct07668752","name":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","nct":"NCT07668752","phase":"3","status":"recruiting"},{"id":"nct07409272","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","nct":"NCT07409272","phase":"3","status":"recruiting"},{"id":"nct07541170","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","nct":"NCT07541170","phase":"3","status":"recruiting"},{"id":"nct07601048","name":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","nct":"NCT07601048","phase":"3","status":"planned"},{"id":"nct06300177","name":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar","nct":"NCT06300177","phase":"3","status":"recruiting"},{"id":"nct07431827","name":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","nct":"NCT07431827","phase":"3","status":"recruiting"},{"id":"nct07262567","name":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","nct":"NCT07262567","phase":"3","status":"recruiting"},{"id":"nct06881784","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","nct":"NCT06881784","phase":"3","status":"recruiting"},{"id":"nct07252232","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","nct":"NCT07252232","phase":"3","status":"recruiting"},{"id":"nct07491445","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","nct":"NCT07491445","phase":"3","status":"recruiting"},{"id":"nct05132075","name":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","nct":"NCT05132075","phase":"3","status":"active"},{"id":"nct06890598","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","nct":"NCT06890598","phase":"3","status":"recruiting"},{"id":"nct07777822","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","nct":"NCT07777822","phase":"3","status":"recruiting"},{"id":"nct06252649","name":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal","nct":"NCT06252649","phase":"3","status":"recruiting"},{"id":"nct07805954","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","nct":"NCT07805954","phase":"3","status":"recruiting"},{"id":"nct07621718","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","nct":"NCT07621718","phase":"3","status":"recruiting"},{"id":"nct04613596","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","nct":"NCT04613596","phase":"2/3","status":"recruiting"},{"id":"precision-panc","name":"Precision-Panc","nct":"ISRCTN14879538","phase":"platform","status":"completed"},{"id":"nct05445843","name":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","nct":"NCT05445843","phase":"2","status":"active"},{"id":"ramp-201","name":"RAMP 201","nct":"NCT04625270","phase":"2","status":"positive"},{"id":"chronos","name":"CHRONOS","nct":"NCT03227926","phase":"2","status":"positive"},{"id":"opus","name":"OPUS","nct":"NCT00125034","phase":"2","status":"positive"},{"id":"nct07209111","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","nct":"NCT07209111","phase":"2","status":"recruiting"},{"id":"nct06936644","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","nct":"NCT06936644","phase":"2","status":"planned"},{"id":"nct07164170","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","nct":"NCT07164170","phase":"2","status":"recruiting"},{"id":"nct07659795","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","nct":"NCT07659795","phase":"2","status":"recruiting"},{"id":"nct07659782","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","nct":"NCT07659782","phase":"2","status":"recruiting"},{"id":"nct07644559","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","nct":"NCT07644559","phase":"2","status":"recruiting"},{"id":"nct06008288","name":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","nct":"NCT06008288","phase":"2","status":"recruiting"},{"id":"nct07784374","name":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast","nct":"NCT07784374","phase":"2","status":"planned"},{"id":"nct07172919","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","nct":"NCT07172919","phase":"2","status":"recruiting"},{"id":"nct07415031","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","nct":"NCT07415031","phase":"2","status":"recruiting"},{"id":"nct07827261","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","nct":"NCT07827261","phase":"2","status":"planned"},{"id":"nct07492680","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","nct":"NCT07492680","phase":"2","status":"recruiting"},{"id":"nct07814417","name":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","nct":"NCT07814417","phase":"2","status":"planned"},{"id":"nct06248606","name":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","nct":"NCT06248606","phase":"2","status":"recruiting"},{"id":"nct05609578","name":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","nct":"NCT05609578","phase":"2","status":"active"},{"id":"combomatch-binimetinib-folfox","name":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations","nct":"NCT05564403","phase":"2","status":"active"},{"id":"nct07492342","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","nct":"NCT07492342","phase":"2","status":"recruiting"},{"id":"nct07198841","name":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","nct":"NCT07198841","phase":"2","status":"recruiting"},{"id":"nct07252739","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","nct":"NCT07252739","phase":"2","status":"recruiting"},{"id":"nct07581912","name":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","nct":"NCT07581912","phase":"2","status":"recruiting"},{"id":"nct06369259","name":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R","nct":"NCT06369259","phase":"2","status":"recruiting"},{"id":"nct07793253","name":"Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer","nct":"NCT07793253","phase":"2","status":"planned"},{"id":"nct05845450","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","nct":"NCT05845450","phase":"2","status":"recruiting"},{"id":"nct07126158","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","nct":"NCT07126158","phase":"2","status":"recruiting"},{"id":"nct07483983","name":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi","nct":"NCT07483983","phase":"2","status":"recruiting"},{"id":"nct06895031","name":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","nct":"NCT06895031","phase":"2","status":"recruiting"},{"id":"nct05853575","name":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","nct":"NCT05853575","phase":"2","status":"active"},{"id":"amplify-7p","name":"AMPLIFY-7P","nct":"NCT05726864","phase":"1/2","status":"negative"},{"id":"nct05379985","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","nct":"NCT05379985","phase":"1/2","status":"recruiting"},{"id":"codebreak-100","name":"CodeBreaK 100 (pancreatic cancer cohort)","nct":"NCT03600883","phase":"1/2","status":"positive"},{"id":"nct07563738","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","nct":"NCT07563738","phase":"1/2","status":"recruiting"},{"id":"nct07286149","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","nct":"NCT07286149","phase":"1/2","status":"recruiting"},{"id":"nct06412198","name":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","nct":"NCT06412198","phase":"1/2","status":"recruiting"},{"id":"nct07020221","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","nct":"NCT07020221","phase":"1/2","status":"recruiting"},{"id":"nct05789082","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","nct":"NCT05789082","phase":"1/2","status":"recruiting"},{"id":"nct07227025","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","nct":"NCT07227025","phase":"1/2","status":"recruiting"},{"id":"nct07259590","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","nct":"NCT07259590","phase":"1/2","status":"recruiting"},{"id":"nct06500676","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","nct":"NCT06500676","phase":"1/2","status":"recruiting"},{"id":"nct05009329","name":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","nct":"NCT05009329","phase":"1/2","status":"active"},{"id":"nct05276726","name":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","nct":"NCT05276726","phase":"1/2","status":"recruiting"},{"id":"nct06667544","name":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","nct":"NCT06667544","phase":"1/2","status":"recruiting"},{"id":"nct06385925","name":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","nct":"NCT06385925","phase":"1/2","status":"recruiting"},{"id":"nct07617805","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","nct":"NCT07617805","phase":"1/2","status":"recruiting"},{"id":"nct05194995","name":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","nct":"NCT05194995","phase":"1/2","status":"active"},{"id":"nct07824960","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","nct":"NCT07824960","phase":"1/2","status":"planned"},{"id":"nct05074810","name":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","nct":"NCT05074810","phase":"1/2","status":"active"},{"id":"nct06243354","name":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","nct":"NCT06243354","phase":"1/2","status":"recruiting"},{"id":"nct05288205","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","nct":"NCT05288205","phase":"1/2","status":"recruiting"},{"id":"nct05358249","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","nct":"NCT05358249","phase":"1/2","status":"active"},{"id":"nct07468071","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","nct":"NCT07468071","phase":"1/2","status":"recruiting"},{"id":"nct06128551","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","nct":"NCT06128551","phase":"1/2","status":"recruiting"},{"id":"nct04699188","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","nct":"NCT04699188","phase":"1/2","status":"active"},{"id":"nct04956640","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","nct":"NCT04956640","phase":"1/2","status":"active"},{"id":"nct07397338","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","nct":"NCT07397338","phase":"1/2","status":"recruiting"},{"id":"nct06162221","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","nct":"NCT06162221","phase":"1/2","status":"recruiting"},{"id":"nct06445062","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","nct":"NCT06445062","phase":"1/2","status":"recruiting"},{"id":"nct05379946","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","nct":"NCT05379946","phase":"1/2","status":"active"},{"id":"nct04585035","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","nct":"NCT04585035","phase":"1/2","status":"active"},{"id":"nct06922591","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","nct":"NCT06922591","phase":"1/2","status":"recruiting"},{"id":"nct05737706","name":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","nct":"NCT05737706","phase":"1"},{"id":"nct06040541","name":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","nct":"NCT06040541","phase":"1","status":"recruiting"}],"pathways":["aml-signalling","autophagy","bcr-abl1-signalling","chemical-carcinogenesis-receptor-activation","choline-metabolism-in-cancer","cml-signalling","colorectal-cancer-signalling","dna-replication-licensing","replication-stress","oncogene-activation-two-hit","drug-efflux-pumps","endometrial-cancer-signalling","fgfr-signalling","gastric-cancer-signalling","glutamine-metabolism","hepatocellular-carcinoma-signalling","lipid-metabolism-cancer","micrornas-in-cancer","nsclc-signalling","pancreatic-cancer-signalling","proteoglycans-in-cancer","ras-mapk","rtk-activation","renal-cell-carcinoma-signalling","resistance-routes-map","thyroid-cancer-signalling"],"companies":["adventris-pharmaceuticals","agilent","amgen","anocca","astellas","bridgebio-oncology-therapeutics","bms","cogent-biosciences","eli-lilly","elicio-therapeutics","erasca","finaldose","frontier-medicines","genfleet","guardant-health","imagene-ai","incyte","inivata","innovent","insilico-medicine","inventisbio","jacobio-pharmaceuticals","kumquat-biosciences","lucence","merck","novartis","qiagen","quanta-therapeutics","revolution-medicines","roche-genentech","tempus","treeline-biosciences","verastem"],"keyPapers":["paper-daraxonrasib-pancreatic-n-engl-j-med-2026","paper-krystal-12-plain-language-summary-future-oncol-2026","paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024","paper-keynote-042-tmb-mutations-ann-oncol-2023","paper-keynote-189-407-tmb-jtocrr-2023","paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023","paper-codebreak-200-lancet-2023","paper-codebreak-300-nejm-2023","paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023","paper-krystal-1-crc-yaeger-nejm-2023","paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","paper-paradigm-jama-2023","paper-giraldo-gallbladder-msk-impact-ccr-2022","paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-drug-dosing-conundrum-nejm-2021","paper-zhang-lung-cancer-never-smokers-nat-genet-2021","paper-topham-subtype-discordant-pancreatic-ccr-2021","paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020","paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020","paper-pishvaian-lancet-oncol","paper-schoenfeld-smarca4-alterations-lung-ccr-2020","paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020","paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019","paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019","paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019","paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019","paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","paper-omori-ipmn-progression-pathways-gastroenterology-2019","paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019","paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019","paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018","paper-loree-tumour-location-continuum-colorectal-ccr-2018","paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","paper-arbour-kras-co-mutation-outcomes-ccr-2018","paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018","paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018","paper-kras-nsclc-cancer-discov-2018","paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","paper-lindeman-lung-molecular-testing-guideline-jto-2018","paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017","paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","paper-tracerx-100-nejm-2017","paper-notta-punctuated-evolution-pancreatic-nature-2016","paper-javle-biliary-ngs-cancer-2016","paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","paper-bailey-molecular-subtypes-pancreatic-nature-2016","paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016","paper-awad-met-exon-14-mutations-lung-jco-2016","paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016","paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015","paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015","paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015","paper-rizvi-mutational-landscape-pd1-science-2015","paper-cms-guinney-nat-med-2015","paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015","paper-tcga-lung-adenocarcinoma-nature-2014","paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014","paper-kris-lung-cancer-mutation-consortium-jama-2014","paper-li-gallbladder-exome-erbb-nat-genet-2014","paper-vogelstein-cancer-genome-landscapes-science-2013","paper-ostrem-kras-g12c-nature-2013","paper-douillard-prime-panitumumab-ras-nejm-2013","paper-bettington-serrated-pathway-colorectal-histopathology-2013","paper-tcga-colorectal-comprehensive-characterization-nature-2012","paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","paper-biankin-pancreatic-exomes-axon-guidance-nature-2012","paper-kanda-panin-1-somatic-mutations-gastroenterology-2012","paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012","paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","paper-wu-gnas-ipmn-sci-transl-med-2011","paper-collisson-pancreatic-subtypes-nat-med-2011","paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009","paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009","paper-jones-pancreatic-core-pathways-science-2008","paper-karapetis-kras-cetuximab-colorectal-nejm-2008","paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","paper-fearon-cell","paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988","paper-almoguera-kras-codon-12-pancreatic-cell-1988"],"hotspots":[{"label":"G12C","position":12,"kind":"activating","frequency":"About 13% of lung adenocarcinomas and 1 to 3% of other solid tumours","drugs":["sotorasib","adagrasib","divarasib","olomorasib","elironrasib","daraxonrasib"]},{"label":"G12D","position":12,"kind":"activating","frequency":"The most common KRAS allele in pancreatic cancer","drugs":["mrtx1133","zoldonrasib","daraxonrasib","eli-002-7p"]},{"label":"G12V","position":12,"kind":"activating","frequency":"Second most common allele in pancreatic and colorectal cancer","drugs":["daraxonrasib","eli-002-7p"]},{"label":"G12R","position":12,"kind":"activating","drugs":["daraxonrasib","eli-002-7p"]},{"label":"G13D","position":13,"kind":"activating","drugs":["daraxonrasib","eli-002-7p"]},{"label":"Q61H/K/L/R","position":61,"kind":"activating","drugs":["daraxonrasib"]},{"label":"Y96D / R68S / H95Q","position":96,"kind":"resistance","drugs":["daraxonrasib"]}],"openQuestions":[{"id":"kras-g12d-clinic","question":"Will KRAS G12D and pan-RAS(ON) inhibitors improve survival in pancreatic cancer, where G12D dominates?","stage":"clinical","actor":"industry","source":{"label":"RASolute 302 (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT06625320"}},{"id":"kras-upfront-combination","question":"Does blocking the adaptive receptor feedback up front (EGFR, SHP2 or SOS1 co-inhibition) beat sequencing after progression?","stage":"clinical","actor":"industry","source":{"label":"CodeBreaK 300, NEJM 2023","url":"https://doi.org/10.1056/NEJMoa2308795"}},{"id":"kras-vaccine-adjuvant","question":"Can shared-antigen KRAS vaccines prevent relapse after surgery in pancreatic and colorectal cancer?","stage":"clinical","actor":"research","source":{"label":"AMPLIFY-7P (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT05726864"}}],"assays":[{"id":"kras-therascreen","name":"therascreen KRAS RGQ PCR Kit","cutoff":"Wild-type required for cetuximab or panitumumab (colorectal); G12C detected for sotorasib and adagrasib (NSCLC)"},{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"guardant360-cdx","name":"Guardant360 CDx","cutoff":"Per companion claim: EGFR (osimertinib), EGFR exon 20 insertions (amivantamab), KRAS G12C (sotorasib), ESR1 mutations (elacestrant), ERBB2 mutations (zongertinib); negative plasma reflexes to tissue"},{"id":"resolution-ctdx-first","name":"Agilent Resolution ctDx FIRST","cutoff":"KRAS G12C detected (adagrasib, NSCLC)"}],"resistance":[{"class":"alk-tki","mechanism":"Bypass signalling (MET, EGFR, KRAS)","category":"bypass"},{"class":"kras-g12c","mechanism":"Adaptive RTK feedback (EGFR, others)","category":"bypass"},{"class":"kras-g12c","mechanism":"Secondary KRAS mutations (Y96D, R68S, H95) and amplification","category":"on-target"},{"class":"kras-g12c","mechanism":"Bypass alterations (MET amplification, NRAS/BRAF mutations, RTK fusions)","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}